⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 20, 2026Expert Review of Respiratory Medicine

When cancer treatment affects the lungs: a clinical overview on pulmonary toxicity induced by new cancer drugs

Dimitrios Komninos Emmanouil Psarros Eva Theochari G Tsirikos Fotios Sampsonas Argyrios Tzouvelekis

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to discuss the pulmonary toxicity associated with new cancer therapies and the importance of monitoring for complications.
Clinical overview of mechanisms related to pulmonary toxicity.
Assessment of risk factors prior to drug administration.
Recommendations for referral to specialized centers for suspected cases.
Emphasizes the high risk of pneumonitis in patients treated with ICIs or TKIs.
Recommends enhanced pharmacovigilance to mitigate risks.

Implication

Clinical overview highlights pulmonary toxicity risks in cancer patients receiving ICIs and TKIs, indicating need for vigilance.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Komninos et al. (2026) studied this question.

synapsesocial.com/papers/699a9d65482488d673cd33e8 https://doi.org/10.1080/17476348.2026.2631816

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach2025 · 4 citations
2Pulmonary toxicity of immune checkpoint inhibitorsReview · 2026 · 1 citations
3Pulmonary Complications of Cancer Therapy: Clinical Presentations, Imaging Patterns, and Management StrategiesClinical Guideline · 2026
4Pneumonitis induced by immune checkpoint inhibitors: a systematic review2025 · 2 citations
5The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis2025

More related papers

Pulmonary Toxicity Caused by Cytotoxic Drugs2006
Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors2026
Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis2025

More from Expert Review of Respiratory Medicine

Heat and childhood respiratory health: exploring the evidence and raising the red flagsTue,
Ki-67 antigen in lung carcinoids/neuroendocrine tumors: from a proliferation marker to a clinical compassTue,